MedTrace Logo

Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma

NCT00096538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-11-25

Study results available
· View outcomes & findings →

Summary

RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma.

PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

valganciclovir

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • New York Presbyterian Hospital

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Susan E. Krown, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096538 on ClinicalTrials.gov